CNM-Au8

The FDA granted breakthrough therapy designation to STK-001 for Dravet syndrome, highlighting its potential to improve upon current treatments by restoring NaV1.1 protein levels.

Clene Inc. has received FDA guidance for a potential accelerated approval pathway for CNM-Au8 in treating amyotrophic lateral sclerosis (ALS).

The HEALEY ALS Platform Trial is pioneering a new approach to accelerate the development of effective treatments for amyotrophic lateral sclerosis (ALS).

The multiple sclerosis (MS) therapeutic landscape is expanding, with over 80 active pipeline therapies currently in development by more than 75 companies.

Clene will meet with the FDA to discuss accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis (ALS).